Genmont Biotech reports Sep revenue NT$45.6M vs NT$31.0M
Genmont Biotech Inc. reported September revenue of NT$45.578M versus NT$31.026M, and Jan-Sep revenue of NT$295.934M versus NT$300.525M, per Taiwan Stock Exchange figures.
Genmont Biotech Inc. said revenue for 2026 was NT$45,578,000, compared with NT$31,026,000 in 2025, according to Taiwan Stock Exchange figures in New Taiwan dollars. Jan-Sep revenue for 2026 was NT$295,934,000 versus NT$300,525,000 for 2025.